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Low malignant potential tumors (borderline) comprise 10–20% of
epithelial ovarian neoplasms and they were ﬁrst described by Taylor
in 1929 (Taylor, 1929; Zanetta et al., 2001). Histologically, they are
deﬁned by atypical epithelial proliferation without stromal in-
vasion. Although the majority are of serous or mucinous histology,
endometrioid, clear-cell, and transitional cell borderline tumors have
been described.
As opposed to womenwith invasive carcinoma, thosewith border-
line tumors tend to be diagnosed at earlier stage and they have amuch
better prognosis than those with invasive carcinoma. The 5-year sur-
vival for women with stage I disease exceeds 95% (Zanetta et al.,
2001). Nevertheless, recurrences have been known to present up to
10–15 years after the initial diagnosis and the 10-year survival ﬁgures
show that some patients eventually die from the disease. Risk factors
for recurrence are the stage of the disease and the presence of
micropapillary features (Burks et al., 1996). The pelvis and abdomen
are the usual sites of recurrences, but spread to other sites occasionally
occurs. Although epidemiologic and biologic data support the idea
that a relationship between invasive and low malignant potential
ovarian tumors exists and that borderline tumors have the potential
to recur as invasive disease, the natural history of progression to inva-
sive ovarian cancer has not been elucidated. The role of chemotherapy
and the radicality of surgical intervention remain controversial
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low malignant potential ovarian tumor that had optimal debulking,
followed by 7 cycles of triple agent chemotherapy, that presents
with a recurrence 25 years later as disseminated lymphadenopathy
with histologic futures consistent with low grade serous ovarian ade-
nocarcinoma. To date, this is the case with the latest reported recur-
rence and demonstrates the importance of continued long term
surveillance, displaying that borderline tumors can behave unpre-
dictably and may recur as overt distant metastatic disease many
years after initial diagnosis.Case
A20 year old nulliparouswoman, initially presentedwith complaints
of increasing abdominal girth, fatiguewith a 20poundweight losswithin
3 months. Physical exam revealed a distended abdomenwithﬂuidwave.
CT abdomen andpelvis showed a complex, cystic pelvicmass and ascites.
The patient underwent an exploratory laparotomy, total abdominal hys-
terectomy, bilateral salpingoophorectomy, omentectomy, appendecto-
my, peritoneal biopsies, pelvic and para-aortic lymph node dissection.
Final pathology showed ovarian borderline papillary serous tumor.
Omentum, pelvic and para-aortic lymph nodes were positive. Of note,
all the implants were non-invasive and there was no focus of low
grade serous carcinoma. The patient was given 7 cycles of triple agent
chemotherapy (adriamycin, cisplatin, cyclophosphamide) and then
she had a negative second look laparotomy. The patient continued to
be on surveillance for the next 18 years with no suggestion of disease
recurrence.
She remained disease free and well for 25 years, when she
presented to her primary care doctor with complaints of a palpable
neck mass, with no other complaints or physical exam ﬁndings. The
neck mass was biopsied and was positive for malignant cells with fea-
tures of low grade adenocarcinoma with psammoma bodies consis-
tent with ovarian origin (Fig. 1). A PET-CT revealed retroperitoneal
lymphadenopathy along the left paracaval lymphatic chain with
SUV 6, lymphadenopathy in the celiac axis with SUV 3.7, right
supraclavicular lymphadenopathy with SUV 6.3, paratracheal and
subcarinal lymphadenopathy with SUV 4.4 (Fig. 2).
Given the diagnosis of recurrent disease, the patient was treated
with Carboplatin and Taxol. After 6 cycles, partial response was
noted with a decrease in CA 125 and the metabolic activity on the
PET scan. Although the regimen was well tolerated, the patient with-
drew from treatment due to social reasons.
Fig. 1. Fine needle aspiration biopsy of right supraclavicular lymph node showing
metastatic serous papillary carcinoma (Papanicolaou stain, 600×). Inset shows a
psammoma body (Diff-Quik stain, 600×).
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The prognosis of low malignant ovarian tumors is excellent with
the majority of the patients being diagnosed at early stage and the
5 year survival exceeding 95% in Stage I tumors (Zanetta et al., 2001).
However, approximately 10% of the patients eventually die of
the disease (Kurman and Trimble, 1993). A unique characteristic of
these tumors is the tendency for late recurrence that affects overall
survival (Casey et al., 1993). Aure et al. (1971) displayed that theFig. 2.Whole-body positron emission tomography scan showing hypermetabolic areas
in neck, mediastinum and retroperitoneum.survival rate of these tumors dropped from 97% to 76% in the 5 to
20 year follow-up time. In addition, Leake et al. (1992) found that
the survival rate dropped from 97% to 89% during the same time
frame.
The development of invasive ovarian carcinoma in patients with
history of borderline ovarian tumors has been well documented in
the literature and the estimated risk is 1–2% without major difference
between serous and mucinous histology (Zanetta et al., 2001).
Although advanced stage and micropapillary features have been rec-
ognized as risk factors for invasive recurrence the biology and natural
history of progression have not been characterized (Kurman and
Trimble, 1993). The aggressiveness of the surgical approach and the
role of chemotherapy are controversial (Trimble, 1998).
The intensity of surgical staging is one of the main issues in the
management of borderline ovarian tumors. Some authors advocate
the use of staging principles applied to invasive ovarian cancer (Lin
et al., 1999). In many cases the diagnosis of borderline tumor is
made postoperatively and a subsequent staging procedure may be
considered. Published data suggest that the risk of recurrence remains
low even without tedious staging (Zanetta et al., 2001). In the view of
the low incidence of recurrence in unstaged patients and the lack of
effective adjuvant treatment the role of aggressive surgical staging
remains controversial. Thorough inspection of the peritoneal cavity
with multiple biopsies, partial omentectomy, and appendectomy is
recommended while the role of retroperitoneal lymphadenectomy
has not been elucidated. Conservative surgery in the form of unilateral
salpingoophorectomy or cystectomy has been associated with a
higher incidence of recurrences, but most recurrences may be sal-
vaged by surgery and the conservative approach is considered reason-
able in young women desiring fertility. Disease related deaths in
patients managed conservatively are very rare. Zanetta et al. (2001)
reported a higher rate of disease recurrence in women undergoing
fertility-sparing surgery (19% v 5%) compared to 150 patients man-
aged by more radical surgery. Thirty-one of thirty-ﬁve recurring in
the contralateral ovary or in the same ovary after cystectomy were
salvaged with repeat surgery alone. Careful preoperative counseling
is recommended. Parity and desire for future fertility should be
discussed so that the patient and surgical team should have a clear un-
derstanding of the surgical plan. Transvaginal ultrasound appears to
be the most effective technique for the surveillance of conservatively
managed patients. Patients undergoing fertility-sparing surgery
often have healthy term infants during the post-treatment period
and an increased risk of ectopic pregnancy or other pregnancy related
complications has not been reported. The diagnosis of ovarian lowma-
lignant potential tumor should not preclude the use of in vitro fertili-
zation when necessary to achieve pregnancy. Deﬁnitive surgery after
successful pregnancies is advocated.(Zanetta et al., 2001; Trimble,
1998).
With regard to postoperative adjuvant treatment, chemotherapy
and radiation have not shown effectiveness due to the low growth frac-
tion of these tumors that is less than the cellular proliferation rate of the
bonemarrow. The risk of death from complications after chemotherapy
or radiation appears to be higher than the risk of death due to progres-
sion to invasive cancer. In some studies the risk or recurrence is higher
amongwomenwho received chemotherapy than among thosewho did
not (Gershenson et al., 1998; Kurman and Trimble, 1993).
In our case an aggressive surgical strategywith total abdominal hys-
terectomy, bilateral salpingoophorectomy, pelvic and paraaortic lymph
node dissection, omentectomy, appendectomy and optimal debulking
was followed. Postoperatively the patient received 7 cycles of chemo-
therapy. The published data suggest that most of the recurrences are
low grade tumors involving pelvic and abdominal structures and can
be salvaged surgically. The clinical and radiologic manifestation of re-
currence in our case was that of multifocal lymphadenopathy and
showed partial response to chemotherapy. Lymphatic diffusion of ovar-
ian cancer is usually retained to the pelvic and para-aortic lymph nodes.
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abdominal lymphatic dissemination is possible although very rare.
To our knowledge this is the case with the longest time interval
prior to recurrence and illustrates that optimization of surveillance
strategies and lifelong follow up is critically important for the patients
with low malignant potential ovarian tumors. Patients with border-
line tumors are usually young and they are at risk for late recurrence
which may not be amenable to surgery even when a radical surgical
approach was followed at the initial diagnosis.
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